L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Prostate Cancer Clinical Trial

Official title:

A Randomized Phase II Dose Finding Study of ArginMax for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated With Radiotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01105130
• Other study ID #: IRB00012793
• Secondary ID: U10CA081851REBAC
• Status: Completed
• Phase: Phase 2
• Start date: October 1, 2010
• Est. completion date: February 4, 2014

Study information

• Verified date: September 2021
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: L-arginine supplements may improve the quality of life and erectile function in men who are prostate cancer survivors. PURPOSE: This randomized phase II trial is studying how well L-arginine supplementation works with or without enzyme inhibitors in treating erectile function and quality of life of prostate cancer survivors previously treated with radiation therapy.

Description:

OBJECTIVES: Primary - To determine the "best dose" (defined as the dose that shows the greatest improvement in the erectile function domain of the International Index of Erectile Function [IIEF] after 8 weeks of therapy) of an L-arginine/Korean ginseng/gingko biloba/damiana-based supplement (L-arginine) to be used in a subsequent phase III trial in prostate cancer survivors previously treated with radiotherapy. Secondary - Evaluate the toxicity of treatment with L-arginine with or without phosphodiesterase-5 inhibitors. - Estimate trial accrual, retention, adherence, and variability. - Assess changes in quality of life (QOL) and sexual function as defined by changes in the QOL of these patients using the Expanded Prostate Cancer Index Composite, changes in the other domains of the IIEF (i.e., orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction), changes in the Sexual Encounter Profile, and changes in the percentage of "yes" (positive) responses to either of the two global efficacy questions. OUTLINE: Patients are stratified according to age (< 65 years vs ≥ 65 years) and current use of phosphodiesterase-5 (PDE-5) inhibitors (yes vs no). Patients are randomized to 1 of 3 treatment arms. - Arm I: Patients receive oral placebo twice daily (total of 6 capsules per day). - Arm II: Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day). - Arm III: Patients receive oral L-arginine twice daily (total of 6 capsules per day). In all arms, treatment continues for 8 weeks in the absence of unacceptable toxicity. Patients may also receive oral sildenafil, tadalafil, or vardenafil (PDE-5 inhibitors). Patients complete the International Index of Erectile Function and the Expanded Prostate Cancer Index Composite-26 at baseline and at weeks 4 and 8. Patients also complete the Sexual Encounter Profile Questionnaire, FACT-P, and the Global Efficacy Questionnaire at weeks 4 and 8.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: February 4, 2014
• Est. primary completion date: February 4, 2014
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

INCLUSION CRITERIA:

• Male prostate cancer survivor previously treated with radiotherapy and who identifies himself as concerned with sexual quality of life, including erectile dysfunction. (seed implants are eligible)
• Had successful sexual activity prior to the commencement of radiotherapy.
• Erectile dysfunction, defined as inability to achieve or maintain an erection sufficient for satisfactory sexual performance
• Interested in sexual activity and agrees to make at least one sexual intercourse attempt with a partner every week during the study.
• The usage of PDE-5 inhibitors will be voluntary and will serve as a stratification factor. Patients taking PDE-5 inhibitors must agree to assume the responsibility for the cost of PDE-5 inhibitor treatment during the protocol period (8 week period) as this is not covered in the cost of the trial.
• Patients currently taking PDE-5 inhibitors sildenafil (Viagra®, Pfizer Pharmaceuticals), tadalafil(Cialis®, Lilly ICOS, LLC), and vardenafil (Levitra®, Bayer Healthcare / Schering Plough Corp.)must agree to take the medication only as prescribed by their treating physician.
• Patients taking PDE-5 inhibitors as part of this study must be on a stable dose of drug for at least one month prior to study entry.
• Must be able to take oral medications.
• > 6 months following completion of all cancer therapy
• No evidence of prostate cancer
• Prior malignancies allowed if no evidence of recurrent disease.
• If previously taken LHRH agonist androgen suppression (e.g, Lupron, Zoladex), anti-androgen (e.g., Casodex, Eulexin, Nilandron), or estrogenic (e.g., diethylstilbestrol) agents, serum testosterone must have returned to the laboratory normal range
• No planned surgery while on protocol or for 4 weeks following completion of protocol
• Prior cystoscopy is permitted.
• Age > 18
• ECOG performance status 0/1.
• Patients must agree not to start taking an herbal product for erectile dysfunction during the eight weeks of study intervention.

EXCLUSION CRITERIA:

• No other concurrent erectile dysfunction therapies permitted (i.e. vacuum pump,cavernosal injections, and other drug therapies). Past use of these and other therapies permitted if the patient can meet the inclusion criteria above.
• No testosterone supplementation permitted.
• Use of LHRH agonist androgen suppression (e.g, Lupron, Zoladex), anti- androgen (e.g., Casodex,Eulexin, Nilandron), or estrogenic (e.g., diethylstilbestrol) agents within the last 6 months.
• Prior prostate or lower genitourinary surgery (bladder, penis, urethra, testicles)including transurethral resection of prostate (TURP). (Prior vasectomy is allowed)
• Serious cardiovascular disease (unstable angina, supraventricular arrhythmia, myocardial infarction, symptomatic congestive heart failure, cardiac arrhythmia, coronary artery bypass surgery within 6 months prior to registration).
• Hypotension (<90/50mm Hg), or uncontrolled hypertension (>170/100 mm Hg)
• Stroke or spinal cord injury within 6 months before registration.
• Patients on Persantine, heparin, Lovenox, warfarin, ginkgo biloba, Plavix, Disalcid, other blood-thinning medication or with a history of bleeding disorders will be excluded.(Aspirin < 325mg allowed)
• Current use of cimetidine, ketoconazole, itraconazole, erythromycin, or ritonavir. Major medical or psychiatric illness which, in the opinion of the investigator, would prevent completion of treatment or would interfere with follow-up.
• Current or prior use of any organic nitrate within the last 6 months (e.g., use of nitroglycerin)
• May not receive other investigational agents or devices during 30 days prior to start of study drug.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to ArginMax (l-arginine, ginseng, or ginkgo biloba)

Related Conditions & MeSH terms

• Erectile Dysfunction
• Male Erectile Disorder
• Prostate Cancer
• Prostatic Neoplasms
• Radiation Toxicity

Intervention

Other:
• Placebo
Given orally

Drug:
• Oral L-Arginine
Given orally 3 capsules ArginMax and 3 Placebo capsules
• Oral L-Arginine
Patients will take 6 capsules of ArginMax twice daily

Locations

Country	Name	City	State
United States	W F Baptist Health	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	International Index of Erectile Function (IIEF)	The International Index of Erectile Function (IIEF) questionnaire consists of 15 questions, each of which is scored on a 0 to 5 or 1 to 5 scale. It is comprised of five domains, each scored as the sum of 2 to 5 questions. Erectile function is the sum of six questions with a range from 1 to 30. Higher scores indicate better functioning.	8 weeks
Secondary	Retention	Retention is the percentage of participants who complete the 8 week visit.	8 weeks
Secondary	Adherence	Adherence is the percentage of prescribed pills taken by the participants	8 weeks
Secondary	Assessment of Quality of Life	Quality of life is quantified by the Functional Assessment of Cancer Therapy - Prostate (FACT_P) questionnaire. The FACT questionnaire is comprised of four subscales - social, emotional, functional, and physical. Each subscale is obtained by summing over 6-7 items, each of which is coded on a 0 to 4 scale. Negatively worded questions are reverse scored and higher scores for each subscale indicate better HRQOL. The social, functional, and physical subscales range from 0 to 28 while the emotional subscale ranges from 0 to 24. The overall score (FACT-G) is the sum over the four subscales and ranges from 0 to 108. Patients also completed 12 questions related to prostate cancer, and the prostate subscale score is the sum of those responses (with some items reverse scored). Scores range from 0 to 48, and as with the other FACT subscales higher scores indicate better HRQOL. FACT-P is the sum of FACT-G and the prostate subscale. This questionnaire was added half-way through the study.	8 weeks